Zydus Lifesciences Ltd - 532321 - Update on board meeting
Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/05/2022 ,inter alia, to consider and approve Update on board meeting. Board will also consider the proposal to buyback equity shares of the Company. Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Post results Q&A session through webinar (powered by Zoom) has been scheduled on the same day i.e. May 20, 2022 at 4:30 pm Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Post results Q&A session through webinar (powered by Zoom) has been scheduled on the same day i.e. May 20, 2022 at 5:00 pm. Jawed Zia named CEO of Cadila Pharmaceuticals' domestic prescription business
Will lead the strategy and business operations of Cadila's branded prescriptions pharma business Zydus Lifesciences Ltd - 532321 - Board to consider FY22 results & Final Dividend on May 20, 2022
Zydus Lifesciences Ltd has informed BSE that the meeting of the Board of Directors of the Company will be held on May 20, 2022 to consider apart from other agenda items to approve the audited financial results for the quarter / year ended on March 31, 2022 and to recommend final dividend for the financial year ended on March 31, 2022.The trading window as per the SEBI Insider Trading Regulations,shall remain closed till May 22, 2022 and shall open for trading on and from May 23, 2022 for all the Directors and Designated Persons. Zydus Lifesciences Ltd - 532321 - Board Meeting Intimation for Notice For The Meeting Of Board Of Directors
Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/05/2022 ,inter alia, to consider and approve The meeting of the Board of Directors of the Company will be held on Friday, May 20, 2022 to consider apart from other agenda items to approve the audited financial results for the quarter / year ended on March 31, 2022 and to recommend final dividend for the financial year ended on March 31, 2022 Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus announces the launch of Bemdac Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press release dated May 6, 2022 titled 'Zydus receives tentative approval from USFDA for Selexipag Tablets' Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press release dated May 3, 2022 titled 'Zydus receives final approval from USFDA for Bortezomib for Injection' Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper advertisement published in the Financial Express English and Gujarati Edition with regard to the Notice to the shareholders for claiming their shares which are proposed to be transferred to Investor Education and Protection Fund ('IEPF').